These mutations result in either gain-of-function or loss-of-function of the receptor; human subjects bearing these mutations show decreased or increased lipid accumulation in adipose tissue, enhanced insulin sensitivity or insulin resistance, dyslipidemia, diabetes, and hypertension [46–50]. The gene discussed is INS; the disease is Insulin resistance.